Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on LinkedIn:
“It’s an honor to be part of this consensus statement from the IASLC Advanced Radiation Technology Subcommittee published today in JTO on radiotherapy to the primary tumor in stage IV NSCLC, led by Drs. Ryan McMahon and Shankar Siva.
Is it time to rethink management of metastatic lung cancer?
Radiotherapy in stage IV NSCLC has typically played a palliative role – but can we leverage the cytoreductive power of radiation to disrupt the biologic evolution of lung cancer and delay or prevent resistance? Encouraging evidence emerging in EGFR mutant NSCLC.
Dogma deserves to be challenged and new strategies are needed to raise the bar. Many caveats and conditions – many questions to be asked and answered.”
Title: Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
Authors: Ryan A. McMahon, Kevin Lee Min Chua, Corinne Faivre-Finn, Andrea R. Filippi, Lizza E.L. Hendriks, Thomas John, Stephen V. Liu, Fiona McDonald, Sanjay Popat, Stephanie P.L. Saw, Pablo Munoz-Schuffenegger, Vamsidhar Velcheti, Alexander V. Louie, Shankar Siva
Read the Full Article.
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: What the New IASLC Consensus Means
